The Company’s founders have an outstanding track record in realizing significant returns for their novel discoveries. The founders have collectively been responsible for over 15 patents and 30 publications with many of their patents leading to the formation of eight companies that have resulted in NASDAQ listings or acquisitions by some of the leading healthcare-pharma players.
Mr. Maguire has over 30 years of global life sciences and healthcare investment banking, management and board experience, raising well in excess of $1billion as an executive and an advisor.
Mr. Maguire co-founded Cannaray Limited in 2018. Cannaray is a medical cannabis and cannabodiol company, operating in the UK and Germany. After closing on a £7.8 million Series A raise, Cannaray through acquisitions quickly became Europe’s second largest (in terms of revenues) cannabis company.
Having recently been Chairman and CEO of Xenetic Biosciences Inc (XBIO), Mr. Maguire turned a life science start-up with a collection of patents into a clinical stage company listed on NASDAQ, a listing he led in 2016. Mr Maguire raised approximately $35M from the private and public markets as well as $20M from strategic investors and originated license agreements in excess of $150M.
In 2007 Mr. Maguire co-founded a UK dialysis services start-up, Renal Services Ltd. He led the £13M fundraising from individuals and institutions for seed capital to Series C. Renal Services is now the second largest provider of dialysis services in the UK with 26 clinics treating approximately
In 2001 he founded Healthcare Capital Partners Ltd, a healthcare and life science corporate finance and proprietary investment boutique which has been responsible for hundreds of millions in investments and exits since its founding. In 1996 he co-founded the Arthur Andersen global healthcare corporate finance practice based in London which he assisted in building from 2 to 35 bankers globally. Scott started his banking career on Wall Street with Merrill Lynch in 1987.
MD, PhD (London), MRCP (London), FRCA (UK), EDIC, FFICM.
Dr Aswani serves as Chief Medical Officer. He is Consultant in Intensive Care Medicine & Anaesthesia at Guy’s and St Thomas’ NHS Foundation Trust, London. He is also Consultant in Intensive Care Medicine at London Bridge Hospital (HCA). Dr Aswani has been dedicated to a top tier career in Intensive Care Medicine and Anaesthesia since 2001. Dr Aswani is the Clinical Lead for Junior Doctors and the Clinical Lead for Vascular Access at Guy’s and St Thomas’. He is Scientific Advisory Board member of Cannaray Ltd.
Dr Aswani undertook extensive training in multiple specialties in the leading clinical institutions in Manchester, Sydney and London. He completed his PhD thesis at Queen Mary University of London (2010-2016) where he studied the role of cell-free circulating DNA released into the circulation in shock states to explain sterile organ injury and death. Dr Aswani introduced a novel therapeutic agent to bind circulating cell-free DNA that resulted in multiple organ protection and improved survival. Dr Aswani continues to perform research in this field and has recently completed preclinical studies for Santersus Ltd.
Mr. Tallett serves as Chief Development Officer. He is B.Sc., MPharm, ABPI, GPhC. Simon has extensive experience in the Healthcare and Life Science areas. After international academic studies in the fields of Microbiology/Virology and Pharmacology, Simon spent several years in various Clinical Pharmacist roles including Aseptics, Cardiology, Nephrology, Respiratory and Immunology. Simon has previous experience in clinical research in the Louise Cootes Centre at Guys and St Thomas Hospital, where he designed and led a research project looking at the effects of smoking on the efficacy of Hydroxychloroquine uptake in Lupus patients – Published in Arthritis & Rheumatism Abstract Supplement of American journal of Rheumatology (Volume 54, Number 9, September 2006) and presented in Washington D.C.
Simon found his early medical passion in Paediatrics whilst working at Great Ormond Street Hospital, London. More recently interests have led him to pursue active roles campaigning for novel therapeutic approaches to be embraced in medicine. Now, as CEO and Founder of Perceptive Edge, Simon has been involved in a variety of pharmaceutical and life science companies – evaluating conceptual ideas and developing and establishing areas of growth and investment opportunities.
Simon holds a B.Sc. from the University of Western Ontario, Canada and Master’s in Pharmacy from University College London School of Pharmacy, England. Simon is a Member of GPhC (General Pharmaceutical Council) and ABPI (Association of British Pharmaceutical Industry).
Aleksander Zaporoztsev joined Santersus AG team with over 20 years of financial experience, 10 of those years of financial and management expertise in the
Mr. Zaporoztsev is a board member of EPhaG AS, Kevelt Pharmaceuticals OY and PJSC Pharmsynthez (MOEX: LIFE) and serves as a chairman of Audit Committee at AS PRFoods (Nasdaq: PRF1T) and at PJSC Pharmsynthez.
Since 2009, Aleksander has held various administrative roles in portfolio companies of Amber Trust S.C.A., a private equity fund.
Aleksander is a partner at FINARTE OU, a financial and management advisory firm.
Prior to joining Amber Trust S.C.A., Mr. Zaporoztsev held multiple financial and administrative positions at the biggest industrial holdings in the Baltic States – BLRT Grupp AS, focused on marine industries and headquartered in Tallinn, Estonia. Aleksander’s earlier experience includes a number of senior financial and management positions at financial and industrial companies in the Baltic States.
Aleksander holds an MBA from Concordia International University, Estonia.
Mr. Zaporoztsev is a strategic finance executive with extensive experience in budgeting and reporting, domestic and international finance, strategic planning, cash flow management, accounting (incl. IFRS), taxation, treasury and business development.